{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"20"}],"title":"Responder"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"108"}],"title":"Non-Responder"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"128"}],"units":"Participants"}],"description":"To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR","groups":[{"description":"Patients with a PDGFRA D842V Mutation, any line of treatment","id":"OG000","title":"Patients With a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy","id":"OG001","title":"2L Patients Without a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy","id":"OG002","title":"3L Patients Without a PDGFRA D842V Mutation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg, including 13 patients enrolled in Part 1","reportingStatus":"POSTED","timeFrame":"Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.","title":"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1","type":"PRIMARY","unitOfMeasure":"Participants"}